Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2005-01-06 Major Shareholding Noti…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 3
Major Shareholding Notification
2005-01-06 English
FORM 424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, describing an offering of common stock by Targeted Genetics Corporation. It includes detailed information about the offering, risk factors, use of proceeds, and company background. This type of document is related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of financial report. The presence of terms like 'prospectus supplement', 'offering', 'shares of common stock', and references to SEC registration and Rule 424(b)(5) clearly indicate this is a capital/financing update document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence score.
2005-01-04 English
FORM 424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, describing an offering of common stock by Targeted Genetics Corporation. It includes detailed information about the offering, risk factors, use of proceeds, and company background. This type of document is related to capital raising activities and financing. It is not a financial report, earnings release, or management discussion, but rather a disclosure document for a securities offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, confirming it is not a brief announcement or regulatory filing. Confidence is high due to the clear identification of the document as a prospectus supplement for a stock offering.
2005-01-04 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 31, 2004. It details the entry into a material definitive agreement, specifically a Collaboration Agreement and a Manufacturing Agreement between Targeted Genetics Corporation and Celladon Corporation. It also discusses a Common Stock Purchase Agreement related to the sale of capital stock. The document includes descriptions of the agreements, terms, and related financial transactions. There are no financial statements or comprehensive financial performance data typical of annual or quarterly reports. The document is not a transcript, proxy, dividend notice, or governance report. It is a regulatory filing reporting a material event (entry into agreements and capital stock sale) as required by the SEC under Form 8-K. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7260 characters) and content support this classification with high confidence.
2005-01-04 English
FORM 10-Q
Interim / Quarterly Report Q3 2004
2004-11-09 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated November 4, 2004, from Targeted Genetics Corporation. It specifically references Item 2.02, which pertains to the results and operations of financial condition, and includes a press release announcing financial results for the quarter ended September 30, 2004. The document states that the press release is furnished as Exhibit 99.1 and is a Current Report on Form 8-K. The length of the document is 3709 characters, which is relatively short and primarily serves to announce the financial results rather than provide detailed financial statements or analysis. According to the classification rules, such a document announcing quarterly financial results in a press release format within a Form 8-K corresponds to an Earnings Release (ER).
2004-11-04 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.